Why Don't Health Workers Prescribe ACT? A Qualitative Study of Factors Affecting the Prescription of Artemether-Lumefantrine by Wasunna, Beatrice et al.
Boston University
OpenBU http://open.bu.edu
Center for Global Health and Development Center for Global Health and Development Papers
2008-2-5
Why Don't Health Workers
Prescribe ACT? A Qualitative Study
of Factors Affecting the Prescription
of Artemether-Lumefantrine
Wasunna, Beatrice, Dejan Zurovac, Catherine A Goodman, Robert W Snow. "Why
don't health workers prescribe ACT? A qualitative study of factors affecting the
prescription of artemether-lumefantrine" Malaria Journal 7:29. (2008)
https://hdl.handle.net/2144/3240
Boston University
BioMed CentralMalaria Journal
ssOpen AcceResearch
Why don't health workers prescribe ACT? A qualitative study of 
factors affecting the prescription of artemether-lumefantrine
Beatrice Wasunna*1,2, Dejan Zurovac2,3,4, Catherine A Goodman2,5 and 
Robert W Snow2,3
Address: 1Eastern and Southern Africa Centre of International Parasite Control (ESACIPAC)/KEMRI, P.O. Box 54840-00200, Nairobi, Kenya, 
2Malaria Public Health & Epidemiology Group, Centre for Geographic Medicine Research-Coast, Kenya Medical Research Institute/Wellcome Trust 
Research Programme, P.O. Box 43640, 00100 GPO, Nairobi, Kenya, 3Centre for Tropical Medicine, University of Oxford, John Radcliffe Hospital, 
Headington, Oxford, OX3 9DU, UK, 4Department of International Health, School of Public Health and Center for International Health and 
Development, 5th Floor, Boston University School of Public Health, 85 East Concord Street, Boston, MA 02118, USA and 5London School of 
Hygiene and Tropical Medicine, Health Policy Unit, Keppel Street, London, WC1E 7HT, UK
Email: Beatrice Wasunna* - bwasunna@nairobi.kemri-wellcome.org; Dejan Zurovac - dzurovac@nairobi.kemri-wellcome.org; 
Catherine A Goodman - cgoodman@nairobi.kemri-wellcome.org; Robert W Snow - rsnow@nairobi.kemri-wellcome.org
* Corresponding author    
Abstract
Background: Kenya recently changed its antimalarial drug policy to a specific artemisinin-based
combination therapy (ACT), artemether-lumefantrine (AL). New national guidelines on the
diagnosis, treatment and prevention were developed and disseminated to health workers together
with in-service training.
Methods: Between January and March 2007, 36 in-depth interviews were conducted in five rural
districts with health workers who attended in-service training and were non-adherent to the new
guidelines. A further 20 interviews were undertaken with training facilitators and members of
District Health Management Teams (DHMTs) to explore reasons underlying health workers' non-
adherence.
Results: Health workers generally perceived AL as being tolerable and efficacious as compared to
amodiaquine and sulphadoxine-pyremethamine. However, a number of key reasons for non-
adherence were identified. Insufficient supply of AL was a major issue and hence fears of stock outs
and concern about AL costs was an impediment to AL prescription. Training messages that
contradicted the recommended guidelines also led to health worker non-adherence, compounded
by a lack of follow-up supervision. In addition, the availability of non-recommended antimalarials
such as amodiaquine caused prescription confusion. Some health workers and DHMT members
maintained that shortage of staff had resulted in increased patient caseload affecting the delivery of
the desirable quality of care and adherence to guidelines.
Conclusion: The introduction of free efficacious ACTs in the public health sector in Kenya and
other countries has major potential public health benefits for Africa. These may not be realized if
provider prescription practices do not conform to the recommended treatment guidelines. It is
essential that high quality training, drug supply and supervision work synergistically to ensure
appropriate case management.
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The World Health Organization (WHO) recommends
that efficacious artemisinin-based combination therapies
(ACTs) should be the preferred replacements for failing
monotherapies, such as sulphadoxine-pyrimethamine
(SP) [1,2]. The Global Fund for AIDS, TB and Malaria is
currently spending millions to fund ACT policy imple-
mentation across Africa. It is, therefore, imperative that
these highly effective drugs reach their target audience.
Kenya implemented a change in its first-line treatment
policy for uncomplicated malaria from SP to the ACT arte-
mether-lumefantrine (AL) in 2006 [3]. AL was supplied by
the Kenyan Ministry of Health (MoH) to all government
health facilities within the district health system – starting
from the lowest level dispensaries, to mid-level health
centres and the higher level district hospitals. Outpatient
care in dispensaries and health centres is most commonly
provided by nurses, while clinical officers are usually out-
patient providers in hospitals. At all government facilities,
AL should be provided to patients free of charge. AL is an
expensive medicine in the private sector, costing from 600
to 680 Kenya Shillings (equivalent to 9–10 US$), putting
it beyond the reach of most households. Government pro-
vision is, therefore, the main delivery channel to the
majority of the poor.
Alongside AL delivery to health facilities, the key imple-
mentation activities during 2006 included in-service
training for health workers, and development and dissem-
ination of national malaria guidelines. The training was
organized in a cascade manner, starting at the national
level by training provincial trainers who then trained dis-
trict trainers who further trained approximately 9,000
health workers [3]. The training was organized outside
health facilities, in the form of 3-day workshops for
approximately 30 participants per training course. These
3-day workshops were facilitated by the District Health
Management Teams (DHMTs). One day was devoted to
the management of uncomplicated malaria, and teaching
modalities included lectures and theoretical case scenar-
ios, but no clinical practice. In support of the implemen-
tation of the new drug policy, a concerted effort was made
to harmonize national case-management guidelines and
training materials [4-6], which were provided to health
workers during the-in-service training sessions.
Between October and December 2006, four to six months
after the policy was deemed rolled out, a facility-based
assessment was undertaken to evaluate the extent to
which febrile patients were managed in accordance with
the revised guidelines in government health facilities [7].
The most important observation of this descriptive study
was that despite AL being in stock on the day of the survey
only 28% of 866 children needing treatment with AL
according to national guidelines were prescribed this
drug. Even of those children seen by health workers who
had attended in-service training, only 43% meeting the
same criteria were prescribed AL. An even more worrying
pattern has been observed in older children and adults
where only 34% of patients seen by trained health work-
ers who diagnosed malaria at facilities with AL in stock
were prescribed AL. This clearly raised concern about
effective implementation of the new drug policy and
prompted a more detailed qualitative investigation on
why health workers might elect not to prescribe AL. These
findings are reported in this paper.
Methods
Malaria treatment guidelines
The new recommendations state that all febrile children
below five years of age and above 5 kg in high malaria risk
areas should be presumptively treated with AL. In low
malaria risk areas, absence of another obvious cause of
fever is used as criterion for treatment. All parts of Kenya
are classified as high malaria risk areas, except for the
highlands of Central and Nairobi provinces. In patients
five years of age and older seen at health facilities where
malaria diagnostics (microscopy or rapid diagnostic tests)
are available, all febrile patients without another obvious
cause of fever should have a malaria test performed, and
health workers should treat with AL when the malaria test
is positive. At health facilities where malaria diagnostics
are not available, all febrile patients should be presump-
tively treated with AL in the absence of another obvious
cause of fever.
Compared with conventional monotherapies, AL has a
more complex six-dose treatment schedule over three
days. The total number of tablets and packaging of AL dif-
fers between four weight categories. Furthermore, lume-
fantrine has poor oral bioavailability; absorption varies
considerably among individual doses and between
patients, and is significantly reduced in the acute phase of
malaria [8-10]. Thus, introduction of AL into clinical prac-
tice requires a greater effort to ensure adherence to diag-
nostic, prescription, drug dispensing and counseling
recommendations. The guidelines, therefore, specify
counseling and drug administration tasks that health
workers should perform when prescribing AL, including
counseling patients on the dosing schedule, importance
of a fatty diet, what to do in case of vomiting, and admin-
istration of the first dose under the health worker's super-
vision.
Study area
The study was conducted in five rural districts of variable
intensities of malaria transmission (Kwale, Kisii, Gucha,
Bondo and Makueni) between January and March 2007.
The study districts, and the structure and provision of clin-
ical services for treating uncomplicated malaria have beenPage 2 of 9
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purposes all districts are classified as high malaria risk
areas and the same malaria case management recommen-
dations apply in all five districts [5]. This qualitative study
was an extension of a larger quantitative study evaluating
the use of AL under operational conditions, which was
conducted in all government health facilities within the
five districts [7].
Sampling of health workers
The quantitative study, undertaken between October and
December 2006, identified 227 health workers located in
193 government health facilities. These health workers
formed the basis of the sampling frame for the present
study. Four criteria were applied to these health workers to
qualify for inclusion in this qualitative study: 1) they must
have received training on the new treatment guidelines; 2)
they were working at health facilities where AL was in
stock on the day of the survey; 3) they were routinely
involved in the diagnosis of malaria at their facility; and
4) during the 2006 facility-based assessment they pre-
scribed AL for less than 40% of patients for whom they
made a routine diagnosis of malaria. This group was
selected deliberately because of their degree of non-adher-
ence, and the lack of other obvious reasons for this. 84
health workers met the first three criteria and 36 met all
four criteria. Of these 36, four did not prescribe AL to any
patients during the assessment, with the remainder pre-
scribing to some but not others. The 36 health workers
were all identified and agreed to participate in the qualita-
tive study. Most of the health workers were nurses (89%).
Only four out of the 36 health workers (11%) were clini-
cal officers. Clinical officers are medical assistants with
three years of training and perform medical duties similar
to those of doctors, with the exception of surgical proce-
dures. Their ages ranged from 25 to over 55 years. Of the
36 health workers most (78%) were working in dispensa-
ries. The other eight were working in health centres (six)
and district hospitals (two) (Table 1).
Data collection methods
Since the study was addressing the sensitive topic of non-
adherence to guidelines, individual in-depth interviews
(IDIs) were selected as the most appropriate data collec-
tion tool to investigate opinions and reasons underlying
such behaviour. A semi-structured interview guide was
developed which allowed for flexibility within the discus-
sions, and explored health worker perceptions about the
new treatment policy and reasons underlying their deci-
sions not to prescribe AL. The influence of perceived sever-
ity of illness on prescribing practices was explored
through a case vignette methodology in which health
workers were asked to respond to a specific case manage-
ment scenario. The guide was piloted in a rural non-study
district (Kirinyaga). Since the qualitative study was an
extension of the quantitative survey the study was intro-
duced to health workers as a follow up of findings of the
preceding quantitative malaria case management study.
Focusing questions on reasons for non-adherence only
could have led health workers to feel defensive and be less
open in their responses. This was avoided by combining
these questions with those on general health worker char-
acteristics, in-service training on the new treatment policy
and health worker perceptions of AL, in order to put
respondents at ease.
The health worker (HW) interviews were augmented with
additional interviews with key informants responsible for
Table 1: Characteristics of health workers stratified by cadre, age, gender and health facility type.
Number Percentage
Number of respondents 36
Number of districts 5
Cadre
Clinical Officers 4 11%
Nurses 32 89%
Age
<25 -
25–34 10 28%
35–44 12 33%
45–55 13 36%
>55 1 3%
Gender
Male 21 58%
Female 15 42%
Health facility type
District hospital 2 5%
Health Centre 6 17%
Dispensary 28 78%Page 3 of 9
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including training facilitators (TF) (10) and DHMT mem-
bers (10). Areas specifically covered with key informants
included the content of the malaria case-management
messages communicated to training participants, drug
supply and programmatic constraints in the implementa-
tion of AL in the districts. All IDIs were conducted by one
of the authors (BW) in English and tape recorded for sub-
sequent coding and analysis. Each session lasted from 45
minutes to one hour 30 minutes.
Data analysis
Information recorded on tape during each IDI was tran-
scribed and subjected to content analysis using N-Vivo,
version 7 qualitative text analysis software (QSR Interna-
tional, Southport, United Kingdom) [13,14]. The process
of analysis involved familiarization with the data, devel-
opment of initial codes based on the research questions
and issues emerging from the data, refinement of codes,
and their allocation to broad themes. Data obtained from
health workers, training facilitators and DHMT members
were compared for purposes of triangulation. For exam-
ple, responses on training messages were triangulated
between health workers and training facilitators. This
process of triangulation ensured completeness and valid-
ity of the findings from each source.
Ethical considerations
Ethical approval was obtained from the KEMRI/National
ethical review committee (KEMRI SSC number 1197).
Before each interview the study objectives, method to be
used (tape recording) and the voluntary nature of partici-
pation was explained to each interviewee and informed
written consent was obtained before the interview began.
Results
The potential factors leading to provider non-adherence
emerging from the in-depth interviews have been organ-
ized into eight broad themes: health worker perceptions
of AL; concerns over cost; fear of stock-outs; excess stocks
of non-recommended antimalarials; ambiguous training
messages; perceived severity of illness; patient pressure to
obtain certain types of anti-malarial; and health system
weaknesses (staffing versus work load and supervision).
Health worker perceptions of AL
It was expected that health workers' negative perceptions
of AL would be a key reason for non-prescription. How-
ever, the data showed that AL was perceived as an effica-
cious treatment compared to SP by nearly all health
workers, and most perceived that the numbers of revisits
had declined since the introduction of AL. Safety was also
not a concern. The majority of health workers reported
that they had not received any cases of patients with side
effects from AL. They further implied that they perceived
AL as having a higher tolerability compared to amodi-
aquine and quinine.
With regard to the dosing schedule for AL, most health
workers felt this was not complex, asserting that the three-
day period was similar to that of amodiaquine and, there-
fore, patients were comfortable with the duration. Health
workers further stated that there were many other drugs
such as antibiotics that were taken over a similar or longer
duration. However, other health workers were of the
opinion that the number of tablets taken per day and the
dosing schedule was cumbersome and likely to compro-
mise compliance. They suggested that a shorter duration
and fewer tablets were likely to improve patient compli-
ance to the treatment regimen.
Concern over AL cost
Health workers were of the opinion that AL was expen-
sive, despite the appreciation that the government had
provided it free at their health facilities. Some stated that,
because it was an expensive drug, they usually restricted
prescription. Health workers had concerns regarding
whether the government would be able to sustain the sup-
ply of AL. One health worker from Makueni District sug-
gested that the introduction of generics might be a
possible solution to reduce costs:
"Can the government ensure the consistent supply of the drug?
The way the drug is being supplied at the moment, I have
doubts that the government will sustain the supply of Coartem
(brand name for AL) unless we bring other generics". (HW,
Makueni)
Fear of stock-outs
Fear of stock-outs was reported in all five study districts.
Health workers reported that the supply of AL had been
inconsistent during the initial stages of implementation of
the new policy and there were shortages of some dosages,
particularly those for adults. Three of the five districts
(Bondo, Makueni and Gucha) had experienced at least
one month of AL stock-out during the three-month period
between December 2006 and February 2007. Nearly all
health workers indicated that they were rationing the drug
because they were not certain of the next supply based on
previous stock-outs periods.
"You may run out of it (AL) and the supply is not certain. In
fact the number of doses we receive is not commensurate to the
number of clients that we see. We are always sure that we will
run short of it in due course. That's why we try to ration".
(HW, Bondo)
As a result, health workers aimed to target the drugs to
those patients they perceived as most in need or most
"deserving".Page 4 of 9
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are limited it could reach a point where you are required to give
AL and you don't have it and you used it on the wrong patient.
Part of the reasoning is that on a daily basis we are giving the
drug to those who 'deserve'. Therefore some will not get AL and
others will. I don't have to give someone who doesn't 'deserve'
it and I always insist on that". (HW, Makueni)
There were also concerns that there might be seasonal
stock-outs at times when there might be an increase in
malaria cases.
Excess stocks of non-recommended antimalarials
DHMT members and health workers in Bondo, Makueni,
Kisii and Gucha reported having received a large supply of
amodiaquine from the Kenya Medical Supplies Agency
(KEMSA) between the months of December 2006 and
February 2007, in contrast to the inadequate supplies of
the recommended AL. This created a difficult position for
some health workers who struggled to understand when
to prescribe AL and how to manage the continued supply
of amodiaquine.
"Actually it was late last month (January, 2007)and early this
month (February, 2007), that they supplied us with both AL
and amodiaquine. So there is that element of confusion to the
health workers. Health workers have complained about being
supplied with amodiaquine in large quantities despite the fact
that they are also getting AL. They are asking why the govern-
ment is still supplying so much of it, if they are not supposed to
use?". (DHMT, Makueni)
These concerns were largely directed to KEMSA.
"I thought this supply was to be wiped out from KEMSA and all
central supply should be having it cut off if it will not be
required. If they are supplied, it means you use it otherwise why
is it being supplied? I'm sure the people from KEMSA know
about AL". (DHMT, Bondo)
The DHMT members added that unless the government
addressed the problem of amodiaquine supply, health
worker prescriptions of AL were likely to be compromised.
Training messages
Some of the key messages delivered during training influ-
enced health workers' prescribing decisions. Incorrect
messages were reportedly received, for example that com-
pulsory parasitological testing was required before pre-
scribing AL, and that amodiaquine was still effective.
Around half of the HWs stated these messages as reasons
for not prescribing AL.
It was widely reported by both those receiving and provid-
ing training that there was a key emphasis during in-serv-
ice training on obtaining confirmed parasitic diagnosis
using microscopy or rapid diagnostic tests (RDTs) before
prescribing AL.
"In the first place when we got this AL we were told not to use
them unless we get those kits (RDTs)". (HW, Kwale)
"We said they have to test before you put the patient on the drug
(AL) and the test has to be positive. We are also encouraging
the use of RDTs even at the dispensary level. So we said there
is no reason for not testing because in the event that you do not
have a microscope, you can use the RDT. That one we empha-
sized, that you have to be tested before prescribing AL". (Train-
ing facilitator (TF), Bondo)
DHMT members indicated that this restriction had pre-
vented many health workers from prescribing AL because
they were waiting for RDTs to be supplied to their health
facilities, particularly to those without microscopy.
The importance of confirmed diagnosis was particularly
emphasized for patients of five years and above. For this
age group health workers reported being told it was com-
pulsory to test before prescribing AL, regardless of the
availability of diagnostics. Only a few health workers said
that they could treat presumptively with AL if diagnostics
were not available. They, therefore, often defaulted to
using monotherapies for older patients.
"We were told that "we don't give Coartem (AL) before testing"
for patients over five years and adults, so our drug of choice
remains as SP, amodiaquine and quinine. Coartem doses for
patients over five and adults are all in the stores as we wait for
the RDTs". (HW, Kwale)
In Makueni, health workers reported that they had been
told by training facilitators that amodiaquine was still
effective and they could, therefore, still prescribe it (this
was confirmed in interviews with training facilitators).
"We were told that amodiaquine still can cure malaria because
92% of the patients get cured when using amodiaquine, while
with Coartem it is 96%. That is why we are still using them".
(HW, Makueni)
Most health workers reported that they were told by train-
ing facilitators to treat all childhood fevers presumptively
as malaria using AL, in accordance with algorithms devel-
oped in the national guidelines and harmonized with the
Integrated Management of Childhood Illness (IMCI) fever
algorithms. However, some health workers reported that
they had been told by training facilitators to rule out other
diagnoses before prescribing AL in febrile children. They
were, therefore, employing some degree of clinical judge-
ment.Page 5 of 9
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fever, you rule out it is not fever as a result of other illness, that
is they were to treat as per IMCI guidelines. However, we told
them every person must be tested to rule out that is not malaria,
and then if it is meningitis or if it is bacterial infection they can
treat according to the IMCI guidelines. They should not treat
fever as malaria". (TF, Kisii)
Perceived severity of illness
The vignette case scenario sought to explore whether the
health worker was more inclined to prescribe AL to a child
<5 years with high temperature (40°C) or to a child with
history of fever but a currently normal temperature and
why. Following from the vignette most health workers
reported that they would prescribe AL to the patient who
had a high temperature but not to those with only history
of fever.
"When a patient comes here (health facility), I check the tem-
perature and if the patient has fever. I do not have a lab here so
I have to give the patient who deserves. The fever has to be high.
So in this story I will give the girl with 37°C amodiaquine
because her fever is not too high maybe there is another illness
so I will investigate further and the other child with tempera-
ture of 40°C I will give AL because the fever is high". (HW,
Kisii)
Patient pressure to obtain a certain type of anti-malarial
Patient pressures were reported by some health workers as
a reason for not prescribing AL. A few health workers
reported that some patients preferred SP to AL because SP
was taken as a single dose, and they could then forget
about the treatment.
Many patients were reported to prefer injections which
were available for quinine, but not AL. In Kwale and Kisii
districts health workers reported that some patients pre-
ferred injections and if they were not given one they felt
they had not received any treatment.
Only two health workers stated that mothers preferred
amodiaquine syrup to AL because they found the six-tab-
let pack cumbersome. The health workers suggested that
an AL suspension/syrup should be provided for children.
"If we can get suspensions for AL because the under fives are
the most that suffer from malaria. You know the mothers are
used to amodiaquine syrup so they usually complain that they
have to crush too many tablets". (HW, Makueni).
Work load and supervision constraints
Under-staffing in the rural health facilities was also
reported as a barrier to adherence to the new treatment
policy. Both health workers and DHMT members indi-
cated that the shortage of staff had resulted in increased
workload thereby affecting the delivery of quality care par-
ticularly in the rural health facilities. DHMT members fur-
ther reported that staff retention was a challenge since
some of the health workers who had been trained on the
new guidelines had moved to other facilities leaving
untrained health workers at the facilities. Staffing issues
were seen as a particular concern in AL prescription
because of the additional time required for counseling,
and direct observation of the first dose, record keeping,
and confirmed diagnosis for patients over five in facilities
with diagnostics.
"We were told to give quality care, it is one thing saying but
another doing. Sometimes you just give quantity care because
I'm all alone here. I have 2–3 community health workers and
they are not conversant with the new treatment policy. Imagine
I am having seven antenatal mothers, six clients of family plan-
ning, fifteen under fives and ten adults. I am the only health
worker and in the prescription of AL it is recommended that one
should take time with that patient so that you can come up with
a good diagnosis, so sometimes I feel harassed. If there could be
additional health workers, then we can give the patient quality
care". (HW, Kwale)
Health workers reported that there had been no supervi-
sory visits following training on the new guidelines. The
DHMT indicated that the inadequacy of supervisory visits
was entirely due to a lack of transport and human
resources to cover the entire district. They further recog-
nized that improved supervision could have corrected any
misinformation conveyed during in-service training.
Discussion
Prescribers' adherence to guidelines is critical for the suc-
cessful implementation of any new drug policy. However,
poor adherence is well described in areas of child health,
family planning and diabetes [15-19]. Discordance
between the observed behaviour of health professionals
and national standard treatment guidelines for uncompli-
cated malaria has been documented in Kenya [12,20],
Malawi [21], Uganda [22,23], Benin [24], Central African
Republic [25], Ghana [26] and Nigeria [27]. A series of
studies in low and middle-income countries have assessed
the relationship between health worker factors, patient-
client factors, health facility environment, administrative
environment and socio-cultural environments on health
worker performance [28-32]. However, little in-depth
qualitative investigation of the reasons behind these asso-
ciations (or lack of associations) has been undertaken.
This study has addressed this gap for the case of prescrip-
tion of ACTs, by investigating health workers' perceptions
and understanding of the new antimalarial treatment pol-
icy, and reasons underlying their non-adherence to the
national antimalarial treatment guidelines.Page 6 of 9
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which they see as more efficacious and more tolerable
than previously used antimalarials such as SP and amodi-
aquine. Adherence to AL has been suggested as a major
constraint to its effectiveness [33]. However, only a few
health workers were concerned about the complexity of
the dosing schedule. Most did not see this as a cause for
non-prescription, as antibiotics and other antimalarials,
with the exception of SP, also had long and sometimes
complex dosing schedules.
The main reasons why sampled health workers reported
that they did not prescribe AL could be grouped into two
broad categories: first, specific failings in the introduction
of this policy, and second, more general health system
issues. The two key specific failings in AL introduction
related to the mixed/unclear and incorrect messages deliv-
ered during in-service training, and the availability/con-
tinued supply of amodiaquine.
KEMSA continued to supply health facilities with large
quantities of non-recommended antimalarials (amodi-
aquine) resulting in confusion among health workers.
This issue had been frequently documented during
changes in antimalarial drug policy with, for example, in
Tanzania stockpiles of chloroquine leading to implemen-
tation problems during SP introduction [34,35]. It is,
therefore, essential that plans are put in place well in
advance of the introduction of new drugs to ensure that
stockpiles of medicines being replaced are removed from
the supply chain.
Mixed or ambiguous messages delivered during in-service
training had a clearly negative impact on health workers'
prescription practices. These included information on the
continued efficacy of amodiaquine, compulsory parasito-
logical testing of patients and differential diagnosis of
fevers in children. In Makueni District, health workers
were universally told that amodiaquine was still effective
and could be used in the treatment of uncomplicated
malaria. This statement is incorrect, since Makueni was
among the first districts in Kenya reporting increased lev-
els of Plasmodium falciparum resistance (22%) to amodi-
aquine as early as in 1997 [36]. Furthermore, such
messages clearly contradict the new guidelines, where
amodiaquine is not recommended in the treatment of
uncomplicated malaria.
With regard to fever in children below five years, some
health workers reported that they were told to rule out
other causes of fever before prescribing AL. This contra-
dicts the main recommendations stipulated in the new
guidelines and accompanying algorithms [5], where pre-
sumptive treatment with AL for all childhood fevers in
high malaria risk areas is recommended. Inappropriate
messages on compulsory malaria diagnosis before pre-
scribing AL are also highlighted in this study. Health
workers reported that they were told during the training
that testing in patients five years and above was compul-
sory regardless of the availability of diagnostics. This con-
tradicts the national treatment guidelines which
recommend that: "Patients above 5 years of age with positive
test result should be treated with AL, however, where diagnos-
tics are not available, in the absence of other obvious cause of
fever AL should be prescribed presumptively for all febrile
patients above 5 years of age" [5]. This confusion was likely
to lead to frequent provision of amodiaquine and SP for
adult patients.
These problems highlight the importance of the quality of
training, a factor rarely captured in quantitative studies on
provider behaviour. It appears that in many cases the
training was effective in getting across the messages deliv-
ered; the problem was that some messages were often
inaccurate. This implies a need for greater quality control
during the training, perhaps through greater time spent on
initial training of trainers, and monitoring of cascade
training sessions by more senior staff. It also emphasizes
the importance of follow up supervision of health workers
in facilities, to monitor their practice, and give them the
opportunity to ask further questions and resolve any con-
fusion.
The second set of reasons for non-adherence related to
more general health system factors, particularly the work-
load of health care staff, and the erratic nature of drug sup-
ply.
The desired quality of care cannot be fully realized when
there is a shortage of health personnel. The Kenyan MoH
faces serious shortages of health personnel, especially
qualified nurses. This has resulted in unskilled staff work-
ing beyond their normal level of competency. The five
study districts have two to four doctors, seven clinical
officers and 40 to 50 nurses per 100,000 people in each
district [37]. In this study, health workers argued that staff
shortages resulting in increased workload affected their
prescribing decisions. This issue was also investigated in a
study on physician practices in the treatment of acute res-
piratory infection, which highlighted the negative rela-
tionship between physician case load and quality of care
[28]. AL prescription requires malaria diagnostic proce-
dures where these are available, adequate counseling,
direct observation of the first dose, and new reporting pro-
cedures, which were argued to be time consuming leading
health workers to prefer prescribing amodiaquine. The
problems of staff shortages may be addressed to some
degree by a recent substantial increase in staff recruitment
in Kenya. The MoH, with funding from the Global Fund,
the US President's Emergency Plan for AIDS Relief (PEP-Page 7 of 9
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health workers, comprising mainly registered and
enrolled nurses (800), laboratory technologists and tech-
nicians (70) and clinical officers (100). The new staff are
not limited to delivering HIV services and will provide
general primary care services. However, despite these
increases, staffing levels remain well below government
norms and the long-term future of these staff appointed
on short-term contracts is unclear.
Many health workers reported drug stock outs as a key rea-
son for non-prescription of AL. AL supply was reported as
erratic in the study districts with at least one stock-out
period since the change in treatment policy. However,
health workers were only included in these interviews if
they were working at health facilities where AL was in
stock on the day of the quantitative survey, but they still
prescribed it for less than 40% of malaria diagnoses. This
indicates that non-prescription may be related to a fear of
future stock outs, and therefore the need to conserve AL
for priority cases, even when the drug is currently in stock.
This is not surprising given the long history and wide-
spread nature of drug stock outs in the Kenyan health sys-
tem occasioned by poor administration and distribution
procedures, and general inefficiencies in the central pro-
curement system [38]. However, several districts in Kenya
are currently moving from the 'push' to 'pull' drug delivery
system where they order AL based on their consumption
requirements, which may help to relieve shortages in the
long-term. The perceived need to conserve AL in case of
future stock outs led health workers to ration the drug
based on their own criteria. They indicated that they
would give AL to patients whom they deemed 'deserving'.
They described a 'deserving' patient as one who appeared
to be more severe, presenting with a high fever/tempera-
ture (40°C), headache and joint pains. The influence of
perceived severity of illness on health worker' prescribing
behaviour has been reported elsewhere [29]. The use of
additional criteria such as these, in discordance with
national guidelines, is likely to result in missed cases of
malaria.
Conclusion
The introduction of free efficacious ACT in the public
health sector in Kenya and other countries has major
potential public health benefits for Africa. These however
may not be realized if provider prescription practices do
not conform to the recommended treatment guidelines. It
is, therefore, paramount to understand reasons underly-
ing health workers' non-adherence to recommended
treatment guidelines. This study investigated factors
affecting health workers' non-prescription of AL.
Some of the key reasons reflect problems in the underly-
ing health system which clearly requires long-term invest-
ment such as staffing levels and drug supply. However,
other key reasons are specifically related to the process of
policy introduction and more amenable to immediate
action, such as inappropriate training messages and con-
tinued supply of non-recommended antimalarials. The
following policy recommendations are implied for both
improving AL delivery in Kenya and informing future pol-
icy change in Kenya and elsewhere. First it is essential that
training, drug supply and supervision work synergistically
to ensure concordance in patient management and
national treatment guidelines. In particular, there is a
need for better quality control of cascade training. Sec-
ondly, single, one-off in-service training efforts, that may
themselves introduce ambiguities in recommendations,
should be augmented with some simple measures of con-
tinuous education, dialogue and clinical supervision.
Finally, a phase-out plan should be developed for non-
recommended antimalarials during the transition period
to prevent mixed prescriptions during the introduction of
a new antimalarial treatment policy.
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